Oncology Case Study
Reprioritizing a Global Oncology Pipeline to Unlock $150M+ in Strategic Value
A top-20 biopharma team moved from fragmented assumptions to expert-validated prioritization with faster capital allocation decisions.
The Situation
A top-20 biopharma company was managing a complex oncology pipeline across multiple tumor types, with significant capital deployed but limited decision clarity.
The Challenge
- Fragmented insights across indications
- Over-reliance on secondary data and internal assumptions
- Lack of real-world validation from oncology experts
Our Approach
ApoInsights (Strategic Intelligence Network)
Activated a global panel of oncology experts across key markets to:
- Validate unmet need across indications
- Assess real-world treatment pathways
- Identify under-recognized clinical opportunities
ApoKynex (KOL Intelligence Platform)
- Structured expert inputs into decision-ready intelligence
- Benchmarked clinical differentiation vs competing assets
- Delivered prioritization frameworks for leadership decisions
Key Insight
Two deprioritized indications demonstrated higher real-world adoption potential and stronger unmet need than current focus areas.
Business Impact
- Reallocated ~$150M toward high-probability assets
- Reduced portfolio decision timelines by 40%
- Strengthened long-term pipeline ROI
Strategic Outcome
From internal assumptions to expert-validated portfolio clarity.
.webp)